Galenvs Sciences is pleased to announce that the company was awarded Phase 1 funding to answer one of the challenges proposed by Innovative Solutions Canada:
Magnetic reagents for detection of COVID-19 and other RNA based molecular diagnostic kits challenge.
Innovative Solution Canada is a program launched by Innovation, Science and Economic Development Canada (ISED), a department of the Government of Canada. This program provides funding for research and development (R&D) of Canadian companies and innovators, all with the aim of encouraging scientific advances and economic development in the country.
Since the outbreak of the COVID-19 pandemic, the Canadian government has been working closely with the scientific industry to understand which areas require urgent investment while building domestic capabilities to fight future pandemics. As part of this effort, several companies have received or will receive funding for their R&D activities to address gaps and challenges related to COVID-19 in Canada.
Galenvs Sciences has proven its ability to create effective solutions in the fight against COVID-19 through its various existing products, including its magnetic nanoparticle-based extraction kits and more specifically its magnetiQ Viral RNA Extraction Kit. The magnetiQ Viral RNA Extraction Kit has been validated by The National Research Council of Canada, the National Microbiology Laboratory, and has received Health Canada approval as a class II COVID-19 medical device.
“Our government is acting quickly to ensure that we are mobilizing our innovation programming and resources to respond to the COVID-19 pandemic. The successful Made-in-Canada projects and proposals announced today will support the researchers and companies that are contributing to the fight against this pandemic. This has remained a top priority for our government and is all part of our continued commitment to protecting the health and safety of all Canadians”– The Honourable Navdeep Bains, Minister of Innovation, Science and Industry
Galenvs Sciences is well-positioned to develop leading-edge solutions to support the national COVID-19 fight effort as the only manufacturer of magnetic nanoparticles in Canada. Based in Montreal, Galenvs specializes in magnetic nanoparticle synthesis and magnetic-based nucleic acid isolation reagent formulation informed by machine learning technology for a wide range of applications including basic and clinical research, and diagnostic procedures.